Skip to main content
. 2020 Sep 3;10:1633. doi: 10.3389/fonc.2020.01633

TABLE 4.

Clinical studies of PRRT treatment for meningioma.

Subjects No. of pts Intervention Dose (GBq) Cycles Tumor response
mPFS (months) Other main results/conclusions References
CR PR SD PD
Recurrent or progressive Ms 5 177Lu-octreotate 14.8–29.6 2–4 0 0 2 3 NA 177Lu-octreotate can have therapeutic effects in meningioma. (99)
Progressive Ms 20 177Lu-DOTATATE 90Y-DOTATOC 13.7–27.6 1–4 0 0 10 10 5.4 PFS6 was 42%; treatment was well tolerated. (100)
Recurrent or progressive Ms 15 90Y-DOTATOC 1.35–14.8 2–4 0 0 13 2 24 Toxicity was moderate. (101)
Progressive unresectable Ms 34 177Lu-DOTATATE 90Y-DOTATOC 1.5–22.2 1–4 0 0 23 11 NA The mean survival 8.6 years; treatment was well tolerated, (102)
Recurrent Ms 29 90Y-DOTATOC 5–15 2–6 0 0 19 10 21 Median OS was 40 months; treatment was well tolerated. (103)
Recurrent Ms 8 111In-Pentetreotide 4.8–29 2–4 0 2 5 1 NA Treatment was well tolerated. (104)
Advanced symptomatic Ms 10 EBRT + 177Lu-DOTATATE or DOTATOC 7.0–7.9 1 1 1 8 0 13.4 The combination treatment was safe and effective. (105)

CR = complete response; DOTATOC = DOTA-(Tyr3)-octreotide; DOTATATE = DOTA-D-Phe1-Tyr3-octreotate;EBRT = External beam radiotherapy; 111In = 111-Indium; 177Lu = 177-Lutetium; mPFS = median progression survival; Ms = meningiomas; NA = not-available; OS = overall survival; PD = progressive disease; PFS6 = 6 months progression survival; PR = partial response; Pts = patients; SD = stable disease; 90Y = 90-Yttrium.